Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Hiroshi Imaoka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0584-0095; OpenAlex author ID A5070985810, A5076202712. Sources: OpenAlex.

Their work

Papers
30 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
115
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: 5 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 5 papers · 2024: 3 papers · 2025: 4 papers · 2026: 1 paper

Papers 30

  1. Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer. Co-author DOI 10.1093/jjco/hyag044↗
  2. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  3. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  4. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  5. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  6. Covered self-expandable metallic stent placement for tumor bleeding from duodenal invasion in patients with unresectable pancreatic cancer. Co-author DOI 10.1002/deo2.361↗
  7. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites. Co-author DOI 10.1016/j.pan.2024.03.015↗
  8. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  9. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  10. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer. Co-author DOI 10.1111/cas.15929↗
  11. Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1186/s13014-023-02367-5↗
  12. Correction: Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1186/s13014-023-02377-3↗
  13. Clinical course of anorexia-cachexia according to type of first-line chemotherapy for advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3048794/v1↗
  14. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  15. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  16. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Co-author DOI 10.3390/diagnostics11071195↗
  17. The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreatic cancer. Co-author DOI 10.1002/cam4.2954↗
  18. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort… First author DOI 10.1007/s00280-020-04110-3↗
  19. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗
  20. Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Co-author DOI 10.2169/internalmedicine.2539-18↗
  21. New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. Co-author DOI 10.3390/jcm8081173↗
  22. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Co-author DOI 10.1002/ijc.30510↗
  23. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  24. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … Co-author DOI 10.1016/j.ejca.2015.11.002↗
  25. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.04.007↗
  26. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.05.007↗
  27. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000446↗
  28. Clinical impact of preoperative endoscopic ultrasound-guided fine-needle aspiration for pancreatic ductal adenocarcinoma. Co-author DOI 10.4103/2303-9027.180472↗
  29. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancrea… Co-author DOI 10.1007/s00535-012-0664-2↗
  30. Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fphys.2013.00269↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Ikeda · 20 shared papers, 2019–2026 · strength 3.07
  2. Mitsuhito Sasaki · 15 shared papers, 2019–2026 · strength 2.27
  3. Shuichi Mitsunaga · 13 shared papers, 2019–2026 · strength 2.02
  4. Junji Furuse · 8 shared papers, 2022–2025 · strength 1.23
  5. Makoto Ueno · 8 shared papers, 2020–2025 · strength 1.18
  6. Tomoyuki Satake · 6 shared papers, 2023–2026 · strength 1.18
  7. Taro Shibuki · 6 shared papers, 2021–2026 · strength 1.14
  8. Naohiro Okano · 7 shared papers, 2022–2025 · strength 1.06
  9. Masato Ozaka · 8 shared papers, 2017–2025 · strength 1.05
  10. Tomonao Taira · 5 shared papers, 2023–2026 · strength 1.00
  11. Kanae Inoue · 5 shared papers, 2023–2026 · strength 1.00
  12. Satoshi Kobayashi · 7 shared papers, 2020–2025 · strength 0.99
  13. Chigusa Morizane · 6 shared papers, 2019–2025 · strength 0.88
  14. Takeshi Terashima · 5 shared papers, 2023–2025 · strength 0.80
  15. Kumiko Umemoto · 6 shared papers, 2020–2025 · strength 0.79
  16. Akihiro Ohba · 5 shared papers, 2022–2025 · strength 0.76
  17. Kohei Nakachi · 4 shared papers, 2023–2025 · strength 0.62
  18. Kunihiro Tsuji · 4 shared papers, 2022–2025 · strength 0.61
  19. Hiroaki Nagano · 3 shared papers, 2025 · strength 0.52
  20. Takuji Okusaka · 4 shared papers, 2019–2023 · strength 0.52
  21. Yasuyuki Kawamoto · 3 shared papers, 2025 · strength 0.51
  22. Nobumasa Mizuno · 8 shared papers, 2013–2023 · strength 0.45
  23. Kazuo Watanabe · 3 shared papers, 2020–2023 · strength 0.43
  24. Yohei Kitano · 3 shared papers, 2022–2025 · strength 0.43
  25. Rei Suzuki · 3 shared papers, 2022–2025 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.